Drug delivery to central nervous system (CNS) diseases is very challenging since the presence of the innate blood–brain barrier (BBB) and the blood-cerebrospinal fluid barrier that impede drug delivery. Among new strategies to overcome these limitations and successfully deliver drugs to the CNS, nanotechnology-based drug delivery platform, offers potential therapeutic approach for the treatment of some common neurological disorders like Alzheimer’s disease, frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson’s disease, Huntington’s disease. This review aimed to highlight advances in research on the development of nano-based therapeutics for their implications in therapy of CNS disorders. The challenges during clinical translation of nanomedicine from bench to bed side is also discussed. Display omitted •Summarize current strategies and new trends of CNS drug.•Emphasis on nanotechnology-based drug delivery systems for CNS management.•Advantages of the nanomedicine therapeutics.•Current trends and challenges in the clinical translation of nanomedicine for CNS disorders.